KLRK1 and colorectal cancer: For example, NKG2D ligands are highly expressed in 83% of colorectal cancer samples, making them a promising candidate target for colorectal cancer trials (NCT05211315); whereas Claudin6 is virtually absent in adult normal tissues, making it an ideal target for treating ovarian and testicular cancers (NCT05410717) [36].